1. Home
  2. EQ vs SWAG Comparison

EQ vs SWAG Comparison

Compare EQ & SWAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQ
  • SWAG
  • Stock Information
  • Founded
  • EQ 2017
  • SWAG 1994
  • Country
  • EQ United States
  • SWAG United States
  • Employees
  • EQ N/A
  • SWAG N/A
  • Industry
  • EQ Biotechnology: Pharmaceutical Preparations
  • SWAG Advertising
  • Sector
  • EQ Health Care
  • SWAG Consumer Discretionary
  • Exchange
  • EQ Nasdaq
  • SWAG Nasdaq
  • Market Cap
  • EQ 24.8M
  • SWAG 20.2M
  • IPO Year
  • EQ 2018
  • SWAG 2021
  • Fundamental
  • Price
  • EQ $0.74
  • SWAG $1.10
  • Analyst Decision
  • EQ Buy
  • SWAG
  • Analyst Count
  • EQ 2
  • SWAG 0
  • Target Price
  • EQ $5.00
  • SWAG N/A
  • AVG Volume (30 Days)
  • EQ 304.3K
  • SWAG 10.7K
  • Earning Date
  • EQ 11-13-2024
  • SWAG 12-03-2024
  • Dividend Yield
  • EQ N/A
  • SWAG N/A
  • EPS Growth
  • EQ N/A
  • SWAG N/A
  • EPS
  • EQ N/A
  • SWAG 0.00
  • Revenue
  • EQ $45,914,000.00
  • SWAG $75,893,871.00
  • Revenue This Year
  • EQ N/A
  • SWAG $11.55
  • Revenue Next Year
  • EQ N/A
  • SWAG N/A
  • P/E Ratio
  • EQ N/A
  • SWAG $594.45
  • Revenue Growth
  • EQ 7.70
  • SWAG 28.74
  • 52 Week Low
  • EQ $0.48
  • SWAG $1.02
  • 52 Week High
  • EQ $3.25
  • SWAG $1.74
  • Technical
  • Relative Strength Index (RSI)
  • EQ 40.86
  • SWAG 47.87
  • Support Level
  • EQ $0.66
  • SWAG $1.10
  • Resistance Level
  • EQ $0.77
  • SWAG $1.19
  • Average True Range (ATR)
  • EQ 0.08
  • SWAG 0.05
  • MACD
  • EQ -0.01
  • SWAG -0.00
  • Stochastic Oscillator
  • EQ 26.09
  • SWAG 25.00

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, It offer its clients with custom sourcing capabilities which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, and event assets, order and inventory management, and designing and hosting online retail popup shops. The company purchases products and branding through various third-party manufacturers and decorators and resells the finished goods to customers.

Share on Social Networks: